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Abstract
In this study we examine the extracellular role of galectin-3 (gal-
3) in joint tissues. Following intra-articular injection of gal-3 or
vehicle in knee joints of mice, histological evaluation of articular
cartilage and subchondral bone was performed. Further studies
were then performed using human osteoarthritic (OA)
chondrocytes and subchondral bone osteoblasts, in which the
effect of gal-3 (0 to 10 μg/ml) was analyzed. Osteoblasts were
incubated in the presence of vitamin D3 (50 nM), which is an
inducer of osteocalcin, encoded by an osteoblast terminal
differentiation gene. Genes of interest mainly expressed in either
chondrocytes or osteoblasts were analyzed with real-time RT-
PCR and enzyme immunoassays. Signalling pathways
regulating osteocalcin were analyzed in the presence of gal-3.
Intra-articular injection of gal-3 induced knee swelling and
lesions in both cartilage and subchondral bone. On human OA
chondrocytes, gal-3 at 1 μg/ml stimulated ADAMTS-5
expression in chondrocytes and, at higher concentrations (5 and
10 μg/ml), matrix metalloproteinase-3 expression. Experiments
performed with osteoblasts showed a weak but bipolar effect on
alkaline phosphatase expression: stimulation at 1 μg/ml or
inhibition at 10 μg/ml. In the absence of vitamin D3, type I
collagen alpha 1 chain expression was inhibited by 10 μg/ml of
gal-3. The vitamin D3induced osteocalcin was strongly inhibited
in a dose-dependent manner in the presence of gal-3, at both
the mRNA and protein levels. This inhibition was mainly
mediated by phosphatidylinositol-3-kinase. These findings
indicate that high levels of extracellular gal-3, which could be
encountered locally during the inflammatory process, have
deleterious effects in both cartilage and subchondral bone
tissues.
Introduction
Osteoarthritis (OA) accounts for 40% to 60% of degenerative
illnesses of the musculoskeletal system. On the whole, approx-
imately 15% of the population suffers from OA. Of these,
approximately 65% are 60 years of age and over. The high
incidence of this illness is rather disturbing since its frequency
increases gradually with the aging of the population.
It is well known that age is a primary risk factor for the devel-
opment of OA, but the mechanisms by which aging contrib-
utes to an increased susceptibility to OA are poorly
understood [1]. The end point of OA is cartilage destruction,
which impairs joint movement and causes pain. In knee joints,
the cartilage destruction is associated with and/or preceded
by subchondral bone alterations [2]. Joint destruction is also
associated with joint inflammation, where the synovial mem-
brane plays a key role [3]. The chronological events of these
phenomena are still debated in the literature. However,
because of the complexity of the disease, its initiation could
occur via any of these tissues, although inflammation of the
synovial membrane is less likely to be a primary cause. In OA,
it would appear that both cartilage and subchondral bone are
altered extracellularly [4-7]. The age-related changes in
chondrocytes result in a metabolic and phenotypic decline,
triggering chondrocytes to be less responsive to growth factor
stimulation and more prone to catabolic stimulation. This
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phenomenon could be the result of biomechanical forces as
well as biological sources, such as cycles of hypoxia, the pres-
ence of reactive oxygen species, accumulation of advanced
glycation end products and the effects of inflammatory
cytokines [8-11]. Indeed, clinically detectable joint inflamma-
tion may predict a worse radiological outcome in OA [12].
Mechanisms by which synovitis exacerbates structural dam-
age in OA are complex. Synovitis induces alterations in
chondrocyte function and in subchondral bone turnover and
enhances angiogenesis [13,14]. Cytokines, such as inter-
leukin-1β and tumour necrosis factor-α, and growth factors are
mainly responsible for these processes. However, another fac-
tor, galectin-3 (gal-3), can be markedly present in OA synovial
tissue during inflammatory phases, in which leukocyte infiltra-
tion occurs [15]. These findings underline the potential delete-
rious role of gal-3 at the pannus level, where activated
macrophages, a type of cell belonging to the leukocyte popu-
lation able to secrete up to 30% of their gal-3, are present
[3,16,17]. This indicates that gal-3 could be found extracellu-
larly in the joint.
The exact role of gal-3 in articular tissues is not yet known. It is
a soluble animal lectin of 30 kDa that preferentially recognizes
lactosamine and N-acetyllactosamine structures [18,19].
Intracellularly, gal-3 is involved in a variety of processes,
including RNA splicing [20], differentiation [21], and apopto-
sis [22]. Extracellularly, it is involved in cell-cell [23,24] or cell-
matrix interactions [25-28]. Our recent work reported the
capacity of normal and OA human chondrocytes to synthesize
gal-3, with an increased expression level in human OA articular
cartilage [29].
In the present study, we further investigate the role of extracel-
lular gal-3 in joint tissues. To this end, we first examined its in
vivo effect in mice having received an intra-articular injection of
gal-3, and further investigated its effect on cells from two OA
articular tissues: cartilage and subchondral bone.
Materials and methods
Intra-articular injection of galectin-3 in mice
Six-week-old 129c/c mice were housed in wire cages in ani-
mal rooms with controlled temperature, humidity, and light
cycles. Mice were allowed food and water ad libitum. Recom-
binant human gal-3 (rh-gal-3) was prepared in our laboratory
and sterilized on a 0.2 μm filter. As the amino acid sequence
of rh-gal-3 shows 85% identical homology and 91% positive
homology with murine gal-3, we injected rh-gal-3 into the
knees of wild-type mice. Mice were distributed into 4 groups
receiving 100 ng, 1 μg or 10 μg of gal-3 or vehicle (PBS)
alone according to previous established protocols [30,31].
After being anaesthetized with isoflurane, a skin incision was
performed on each knee and a single injection of gal-3 or PBS
administered under the patellar ligament using a Hamilton
syringe with a 26G3/8 intradermal needle. The day of injection
was considered day 0 (D0); the animals were sacrificed 4
days after the injection. The study was performed according to
the Canadian Council on Animal Care regulations and was
approved by the Animal Care Committee of the University of
Montreal Hospital Centre.
Knee joint swelling calculation
Animals were examined daily and knee diameter was meas-
ured using a digital calliper (model #2071M, Mitutoyo Corpo-
ration, Kawasaki, Japan) as described by Williams and
colleagues [32]. The swelling corresponded to the difference
between joint diameter measured every day and joint diameter
prior to the injection.
Cartilage histological grading
Histological evaluation was performed on the sagittal sections
of the mouse knees removed at D4. Specimens were dis-
sected, fixed in TissuFix #2 (Laboratoires Gilles Chaput, Mon-
treal, QC, Canada), decalcified in RDO Rapid Decalcifier for
bone (Apex Engineering, Plainfield, IL, USA), and embedded in
paraffin. Serial sections (5 μm) were stained with safranin O
and toluidine blue. The modifications in cartilage and subchon-
dral bone were graded on a scale of 0 to 20 by two blinded,
independent observers using a histological scale modified
from Mankin and colleagues [33]. This scale was used to eval-
uate the severity of modifications based on the loss of staining
with toluidine blue (scale 0 to 4), cellular changes (scale 0 to
4), surface/structural changes in cartilage (scale 0 to 5), struc-
ture of the deep zone of cartilage (scale 0 to 4), and subchon-
dral bone remodelling (scale 0 to 3). Scoring was based on
the most severe histological changes within each cartilage and
subchondral bone section.
Subchondral bone morphometry
The sections (5 μm) of each specimen were subjected to
safranin O staining, as previously described [34]. A Leica
DMLS microscope (Leica, Weitzlar, Germany) connected to a
personal computer (Pentium III, using Image J software,
V.1.27, NIH, USA) was used to perform the subchondral bone
morphometry analysis. The subchondral bone surface (μm)
was measured on each slide in two 500 μm × 250 μm boxes,
using as the upper limit, the calcified cartilage/subchondral
bone junction as previously described [34]. Two measure-
ments were done and averaged for each section.
Human osteoarthritis specimens
Femoral condyles and tibial plateaus were obtained from 15
OA patients (9 female and 6 male; aged 67 ± 9 years) follow-
ing total knee arthroplasty. All patients were evaluated by a
certified rheumatologist and, based on the criteria developed
by the American College of Rheumatology Diagnostic Sub-
committee for OA [35], were diagnosed as having OA. This
procedure was approved by the Ethics Committee of the Uni-
versity of Montreal Hospital Centre.Available online http://arthritis-research.com/content/9/1/R20
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Human chondrocyte culture
Chondrocytes were released from the articular cartilage by
sequential enzymatic digestion at 37°C, as previously
described [36,37] and cultured in DMEM (Invitrogen, Burling-
ton, ON, Canada) supplemented with 10% FBS (Invitrogen)
and an antibiotic mixture (100 units/ml penicillin base, 100 μg/
ml streptomycin base; Invitrogen) at 37°C in a humidified
atmosphere of 5% CO2/95% air. Only first-passage cultured
OA chondrocytes were used in the study. OA chondrocytes
were seeded at 1 × 105 cells in 12 well plates in DMEM con-
taining 10% FBS for 48 h; the medium was then replaced for
24 h by DMEM containing 0.5% FBS, after which the cells
were incubated for 24 h in fresh media containing 0.5% FBS
in the absence or presence of rh-gal-3 (0 to 10 μg/ml).
Subchondral bone osteoblast culture
The overlying cartilage was removed from the tibial plateaus,
and the trabecular bone tissue was dissected from the
subchondral bone plate. Primary subchondral osteoblasts
were released as previously described [38]. Briefly, subchon-
dral bone samples were cut into small pieces of 2 mm2 before
sequential digestion in the presence of 1 mg/ml collagenase
type I (Sigma-Aldrich, Oakville, ON, Canada) in DMEM without
serum at 37°C for 30, 30, and 240 minutes. After being
washed with the same medium, the digested subchondral
bone pieces were cultured in DMEM containing 10% FBS.
This medium was replaced every two days until cells were
observed in the petri dishes. At confluence, cells were pas-
saged once in 12- or 24-well plates in DMEM containing 10%
FBS. Experiments were performed in DMEM containing 0.5%
of charcoaled FBS with or without 50 nM 1,25 [OH]2 D3 (1,25-
dihydroxycholecalciferol; vitamin D3) in combination or not
with gal-3. To evaluate signalling pathways involved in vitamin
D3-stimulated osteocalcin production that are inhibited by gal-
3, cells were pre-incubated for 2 h with specific inhibitors and
then incubated for 22 h in the presence of the inhibitors and
vitamin D3 in combination or not with gal-3. The inhibitors used
were KT5720 (inhibitor of protein kinase A; final concentration
2 μM), KT5823 (inhibitor of protein kinase G; final concentra-
tion 2 μM), Genistein (broad inhibitor of tyrosine kinase; final
concentration 20 μM), Taxifolin (an antioxidant flavonoid; final
concentration 1 μM), wortmannin (inhibitor of phosphatidyli-
nositol 3-kinase (PI 3-kinase); final concentration 250 nM),
PD98059 (inhibitor of mitogen-activated protein kinase
kinase-1 (MEK-1) activation; final concentration 10 μM), and
SB202190 (inhibitor of p38 mitogen-activated protein kinase;
final concentration 2 μM). All inhibitors were purchased from
Calbiochem (San Diego, CA, USA).
Real time RT-PCR
RNA extraction and real time RT-PCR were performed as pre-
viously described [29]. Primers for the genes encoding a dis-
integrin and metalloproteinase with thrombospondin type 1
motif (ADAMTS)-5 (aggrecanase-2), matrix metalloproteinase
(MMP)-3 (stromelysin), osteocalcin, alkaline phosphatase and
type I collagen α1 chain were synthesized by Invitrogen (Table
1). Data analysis was carried out using the Gene Amp 5700
Sequence Detector System software (Applied Biosystem,
Foster City, CA, USA) and values normalized to the ribosomal
subunit 18S. Specific primers for type I collagen α1 chain
were designed using Primer3 software [39].
Osteocalcin determination
The assay measured only intact human osteocalcin and was
performed on human osteoblast-conditioned media using a
specific enzyme immunoassay (EIA) kit with a sensitivity of 0.5
ng/ml (Biomedical Technologies Inc., Stoughton, MA, USA).
Protein determination
Cells were lysed in 0.5% sodium dodecylsulfate and proteins
quantified with the bicinchoninic acid assay [40].
Table 1
Primers used for RT-PCR
Amplified gene product Primers Base pairs Reference
ADAMTS-5 S: GGCATCATTCATGTGACAC
AS: GCATCGTAGGTCTGTCCTG
364
MMP-3 S: GAAAGTCTGGGAAGAGGTGACTCCAC
AS: CAGTGTTGGCTGAGTGAAAGAGACCC
284
Osteocalcin S: CATGAGAGCCCTCACA
AS: AGAGCGACACCCTAGAC
310 [48]
Alkaline phosphatase S: TGCAGTACGAGCTGAACAG
AS: TGAAGACGTGGGAATGGTC
267
Type I collagen α1 chain S: CCGAAGGTTCCCCTGGACGA
AS: CGCCCTGTTCGCCTGTCTCA
252
18S S: GAATCAGGGTTCGATTCCG
AS: CCAAGATCCAACTACGAGC
279 [29]
S, sense; AS, antisense.Arthritis Research & Therapy    Vol 9 No 1    Janelle-Montcalm et al.
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Statistical analysis
Data are expressed as mean ± SEM or median (range). Statis-
tical analyses were the Mann-Whitney U and the two-tailed
Student's  t-tests for animal experiments and cell culture,
respectively. Results of p < 0.05 were considered significant.
Results
Intra-articular injection of galectin-3
As Ohshima and colleagues [15] showed that gal-3 was mark-
edly present in OA synovial tissues during the inflammatory
phase and could be recovered in the synovial fluid, we
explored the potential extracellular role of gal-3. We injected
gal-3 (0.1, 1, and 10 μg) into the knee joints of mice. To eval-
uate the potential role of gal-3 in the inflammation process we
first determined if this molecule induces joint swelling. Data
show that the vehicle alone (control) induced a joint swelling
at D1 (p ≤ 0.0002 versus D0) (Figure 1). Although joint swell-
ing at D2 was significantly lower compared to D1 (p < 0.005),
a significant difference was still seen when D2 was compared
to D0 (p < 0.004). Values gradually returned to the basal con-
ditions. Gal-3 exacerbated and extended the swelling; thus, at
D2, gal-3 injections of 0.1, 1, and 10 μg significantly induced
higher swelling than the vehicle alone (p < 0.05, p < 0.004
and p < 0.002, respectively). This effect was sustained the
third day post-injection (p < 0.006 for 0.1 μg, p < 0.002 for 1
μg, p < 0.0001 for 10 μg). Finally, at D4, values tended to
return to those of the control group, although gal-3-induced
joint swelling was still statistically significant (p < 0.006) with
Furthermore, we investigated the effect of gal-3 on cartilage
and subchondral bone using histological means. The global
histological score (median and (range)) in the control group
was 5.0 (3.5 to 6.0) whereas it reached 9.5 (7.0 to 12.5) (p <
0.04 versus control), 10.5 (8.5 to 12.5) (p < 0.02 versus con-
trol) and 13 (p < 0.04 versus control) in the gal-3-injected
group with 0.1, 1, and 10 μg gal-3, respectively (Figure 2a).
The cartilage score in the control group was 3.0 (2.0 to 4.0)
whereas it reached 4.0 (3.5 to 5.5), 6.5 (7.5 to 5.5) (p < 0.02
versus control) and 8 (p < 0.04 versus control) in the gal-3-
injected group with 0.1, 1, and 10 μg gal-3, respectively (Fig-
ure 2b). The subchondral score in the control group was 2.0
(1.0 to 2.5) whereas it reached 3.5 (3.0 to 4.5) (p < 0.04 ver-
sus control), 4.0 (3.0 to 5.0) (p < 0.04 versus control) and 5
(p < 0.04 versus control) in the gal-3-injected group with 0.1,
1, and 10 μg gal-3, respectively (Figure 2c). Therefore, both
Figure 1
Mouse knee swelling measurement Mouse knee swelling measurement. Galectin-3 (gal-3) was injected in 
both knees. Animals were examined daily and knee diameter measured 
using a digital calliper as described in Materials and methods. The 
swelling corresponded to the difference between joint diameter meas-
ured every day and joint diameter prior to the injection (D0). D0 was 
given the value of 0. Control (Ctl): injection of PBS. Each group con-
tained four animals. *p versus same conditions as D0; #p versus control 
of the corresponding day.
Figure 2
Histological score for mice four days after intra-articular galectin-3 (gal- 3) injection Histological score for mice four days after intra-articular galectin-3 (gal-
3) injection. (a) Total score, (b) cartilage score and (c) bone histomor-
phometric score. Data are expressed as median and (range) and are 
presented in box plot, where the boxes represent the 1st and 3rd quar-
tiles, the line within the box represents the median, and the lines out-
side the box represent the spread of the values. Control (Ctl): mice 
injected with PBS. P versus control group; n = four animals per group.Available online http://arthritis-research.com/content/9/1/R20
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the cartilage parameters (structure/surface, cellularity, and
toluidine blue staining) and the subchondral bone surface
were modified by the gal-3 injection (Figure 3). These modifi-
cations are illustrated in Figure 3, which shows changes in the
surface, in cellularity and remodelling of the deep layers in the
presence of gal-3 (left panel (b-d)) compared to the control
group. Destaining and modification of cell columns were also
noticed in the presence of gal-3 (left panel (f-h)) compared to
the control group.
Effects of galectin-3 on chondrocytes and osteoblasts
Effect of galectin-3 on ADAMTS-5 and MMP-3 in human 
OA chondrocytes
In vivo data strongly suggest that extracellular gal-3 affects
both chondrocytes and osteoblasts. We therefore further
explored the effects of gal-3 on human OA cells and examined
enzymes and markers of these cells. For chondrocytes, two
major enzyme systems were evaluated: ADAMTS-5 and MMP-
3. Data show that human OA chondrocytes incubated with rh-
gal-3 for 24 h increased ADAMTS-5 expression in a biphasic
mode. Indeed, it is interesting to note that this gene is very
sensitive to gal-3 since a concentration as low as 0.25 μg/ml
is sufficient to significantly enhance its expression. Another
peak of stimulation was obtained with a concentration of 5 μg/
ml (Figure 4). MMP-3 expression was only slightly induced at
low concentration and significance was reached at 5 μg/ml
with a major increase obtained at 10 μg/ml (Figure 4).
Effects of galectin-3 on osteoblastic markers in human OA 
subchondral bone osteoblasts
The effects of gal-3 on human osteoblasts were evaluated in
the presence or absence of vitamin D3, which allows the termi-
nal differentiation of these cells. Alkaline phosphatase expres-
sion was increased with gal-3 at 1 μg/ml (p < 0.04), but not at
10 μg/ml (Figure 5a). In contrast, the latter concentration trig-
gered significantly lower alkaline phosphatase expression than
1 μg/ml (p < 0.04). Alkaline phosphatase, which is upregu-
lated by vitamin D3, tended to be increased with gal-3 at 1 μg/
ml (p < 0.07). A significant difference in alkaline phosphatase
expression was found between osteoblasts treated with
vitamin D3 in the presence of 1 μg/ml gal-3 and vitamin D3 in
the presence of 10 μg/ml gal-3 (p < 0.03).
As previously described, in the absence of vitamin D3, osteo-
calcin expression was maintained at a minimal level, and gal-3
had no effect on osteocalcin expression (Figure 5b). In con-
trast, in the presence of vitamin D3, gal-3 induced a dose-
dependent inhibition of osteocalcin expression. Indeed, vita-
min D3 alone stimulated a 43-fold increase in osteocalcin
Figure 3
Representative histological sections of specimens from mice stained  with (a-d) safranin O or (e-h) toluidine blue (magnification ×100) Representative histological sections of specimens from mice stained 
with (a-d) safranin O or (e-h) toluidine blue (magnification ×100). Con-
trol group (a,e). Mice were injected with 0.1 μg (b,f), 1 μg (c,g), or 10 
μg (d,h) galectin-3.
Figure 4
Effects of exogenous galectin-3 (gal-3) on human osteoarthritis  chondrocytes Effects of exogenous galectin-3 (gal-3) on human osteoarthritis 
chondrocytes. Chondrocytes were treated with increasing concentra-
tions of recombinant human gal-3. Both ADAMTS-5 and matrix metallo-
proteinase (MMP)-3 expression were analyzed by real time RT-PCR. P 
versus control (Ctl); n = 5.Arthritis Research & Therapy    Vol 9 No 1    Janelle-Montcalm et al.
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expression compared to the basal level, whereas the addition
of either 1 μg/ml gal-3 or 10 μg/ml gal-3 with vitamin D3
induced osteocalcin expression to only 26.5 (p < 0.04) and
6.5 (p < 0.0001) times the basal level, respectively. These
results were confirmed at the protein level by analyzing osteo-
calcin concentration in conditioned media using an EIA. Oste-
ocalcin production was inhibited by around 40% and 85% at
gal-3 concentrations of 1 and 10 μg/ml, respectively (Figure
5b, insert). We verified the inhibition of osteocalcin production
with a commercially available rh-gal-3 (R&D Systems, Minne-
apolis, MN, USA). Results obtained from these experiments
were 138.7 ± 21.2 (mean ± SEM; ng/mg protein; n = 3) for
osteoblasts treated with vitamin D3 alone, 67.6 ± 7.9 for those
treated with 1 μg/ml rh-gal-3 in the presence of vitamin D3 and
2.4 ± 0.9 for cells treated with 10 μg/ml rh-gal-3 in the pres-
ence of vitamin D3. In addition, we made a truncated isoform
of gal-3 (Gly108 to Ile249) corresponding to the carbohydrate
recognition domain (CRD). This truncated isoform is known to
be incapable of multimerizing and it is unable to reproduce the
effects of whole gal-3. Results obtained with an EIA were
130.2 ± 16.5 (mean ± SEM; ng/mg protein; n = 7) for oste-
oblasts treated with vitamin D3 alone, 158.5 ± 22.6 for those
treated with 1 μg/ml CRD in the presence of vitamin D3 and
163.4 ± 26.1 for those treated with 5 μg/ml CRD in the pres-
ence of vitamin D3. As expected, CRD was not able to down-
regulate the osteocalcin production.
As 10 μg/ml gal-3 almost entirely inhibited osteocalcin pro-
duction, we further examined the signalling cascades of gal-3
inhibition of vitamin D3-stimulated osteocalcin production with
5 μg/ml gal-3, which resulted in an inhibitory effect closer to
50% (Figure 6). Vitamin D3-stimulated osteocalcin production
tended to be inhibited by genistein (35%) and SB202190
(40%), indicating that tyrosine kinases and p38 mitogen-acti-
vated protein kinase may be slightly involved (Figure 6). How-
ever, the addition of gal-3 in the presence of these inhibitors
still induced further inhibition, which was statistically signifi-
cant (p < 0.006 and p < 0.005, respectively), indicating that
gal-3 did not induce these pathways. The combination of gal-
3 with either KT5720 or KT5823 also significantly inhibited
osteocalcin production compared to their respective controls
(p < 0.008 and p < 0.01, respectively), indicating that neither
protein kinase A nor protein kinase G are involved in gal-3-
inhibited osteocalcin production. This result was confirmed by
the fact that gal-3 alone and gal-3 in the presence of KT5823
did not produce results with a significant difference. In con-
trast, PD98059 prevented further inhibition of osteocalcin pro-
duction by gal-3. This result indicates that Erk1/Erk2 kinases
are also involved to some extent in gal-3 signalling transduc-
tion. Taxifollin, an antioxidant flavonoid, also seemed to prevent
gal-3 inhibition of osteocalcin production, but this inhibitor had
the weakest effect. The most spectacular result was obtained
with an inhibitor of PI 3-kinase, wortmannin, which totally pre-
vented the inhibition of osteocalcin by gal-3.
As type I collagen is the most abundant protein of the osteoid,
we finally investigated whether gal-3 affects expression of the
type I collagen α1 chain in subchondral bone osteoblasts. In
the absence of vitamin D3, 10 μg/ml of gal-3 inhibited 50% of
type I collagen α1 chain expression (p < 0.02) but this inhibi-
tory effect was partly reversed by vitamin D3 (Figure 7).
Discussion
In the present study, we show that extracellular gal-3 induced
swelling and OA-like lesions in the knee joints of mice. These
findings were confirmed by the experiments in which we dem-
onstrated in human OA chondrocytes that gal-3 stimulated the
expression of ADAMTS-5 and MMP-3, the main enzymes
involved in proteoglycan degradation in cartilage. Furthermore,
using human osteoblasts, we showed that gal-3 inhibited oste-
ocalcin production, which is encoded by the most specific and
latest gene expressed by differentiated osteoblasts.
Figure 5
Effects of exogenous galectin-3 (gal-3) on markers of subchondral  bone osteoblasts Effects of exogenous galectin-3 (gal-3) on markers of subchondral 
bone osteoblasts. Osteoblasts were treated with 1 or 10 μg/ml of 
recombinant human gal-3 in the presence or absence of vitamin D3. 
Both (a) alkaline phosphatase and (b) osteocalcin expression were 
analyzed by real time RT-PCR. Insert illustrates the protein level of oste-
ocalcin. N = 4.Available online http://arthritis-research.com/content/9/1/R20
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Results obtained by Ohshima and colleagues [15] demon-
strated that intra-articular production of gal-3 could occur in
joints even during OA, and particularly during inflammatory
phases. Very often, these phases lead to hyperplasia of the
synovium, which may invade the joint space and adhere to car-
tilage, generating a pannus. This pannus is composed of very
active cells such as leukocytes and, most importantly, macro-
phages, which are able to secrete high levels of gal-3 when
they are activated. Therefore, we injected gal-3 into the knee
joints of mice and evaluated the structural changes. We found
that gal-3 induced a swelling that was sustained compared to
injection of PBS alone. Moreover, gal-3 injection generated
lesions that affected both cartilage and subchondral bone
tissue.
It is interesting to note that two major enzymes responsible for
proteoglycan degradation were stimulated by gal-3. This find-
ing corroborates the in vivo data, in which cartilage presented
with both alterations and fainter staining with toluidine blue in
gal-3 injected mice. However, not all MMPs were stimulated
by gal-3 in chondrocytes, since collagenase-3 (MMP-13) was
unaffected (data not shown). In addition, the level of tissue
inhibitor of MMP-1 (TIMP-1), a natural protein inhibitor
produced by chondrocytes, also remained stable (data not
shown). We show that ADAMTS-5 was more sensitive than
MMP-3 to gal-3, since its expression was stimulated with very
low concentrations of gal-3, unlike MMP-3, which required
higher concentrations for stimulation. The regulation of
ADAMTS-5 is crucial since it was recently demonstrated by
two independent groups (using knock-out mouse models) that
ADAMTS-5 is the major aggrecanase responsible for prote-
oglycan degradation in cartilage destruction [41,42]. On the
other hand, we so far have no explanation for the rebound
phenomenon observed for ADAMTS-5 stimulation with 1 μg/
ml gal-3.
Gal-3 not only modulated chondrocyte-expressed genes but
also those of osteoblasts. More particularly, production of
osteocalcin, which is an osteoblastic marker [43], was
strongly inhibited by gal-3. Furthermore, the multimerization of
gal-3 is needed to induce this effect since the CRD, which is
a truncated isoform of gal-3 lacking this property, has no
effect. The membranous target recognized by gal-3 is still
unknown in osteoblasts. However, among other targets, gal-3
is able to bind integrin β1. Interestingly, a recent study
reported that the downregulation of integrin β1 with either
small interfering RNA or blocking antibodies decreased the
vitamin D3-stimulated osteocalcin level [44]. One hypothesis is
that gal-3 may act, at least partially, by blocking integrin β1 at
the osteoblast surface. Among different cascades of regula-
tion involved in the inhibition of vitamin D3-stimulated osteocal-
cin levels, the PI 3-kinase appears to be a key enzyme. This
could be related to the implication of integrins, since it has
recently been shown that several biological functions of oste-
oblasts are regulated via the integrin/PI 3-kinase pathway
[45,46].
Unlike osteocalcin, type I collagen α1 chain expression was
downregulated only with a high gal-3 concentration. However,
vitamin D3 prevented the inhibition of type I collagen expres-
sion. This latter finding raised the potential role of gal-3 in pre-
venting osteoid matrix formation during the inflammatory
process, particularly in individuals with low or depleted levels
Figure 6
Signalling pathways of inhibition by galectin-3 (gal-3) of vitamin D3- stimulated osteocalcin production Signalling pathways of inhibition by galectin-3 (gal-3) of vitamin D3-
stimulated osteocalcin production. Osteoblasts were treated with 5 μg/
ml of recombinant human gal-3 in the presence of vitamin D3 and oste-
ocalcin was determined. Inhibitor concentrations were: KT5720, 2 μM; 
KT5823, 2 μM; Genistein (Genist.), 1 μM; Taxifollin, 1 μM; wortmannin 
(Wortma.), 250 nM; PD98059, 10 μM; and SB202190, 2 μM. *P ver-
sus the autologous control; n = 5.
Figure 7
Effects of exogenous galectin-3 (gal-3) on type I collagen expression in  osteoblasts Effects of exogenous galectin-3 (gal-3) on type I collagen expression in 
osteoblasts. Osteoblasts were treated with 1 or 10 μg/ml of recom-
binant human gal-3 in the presence or not of vitamin D3. Collagen type I 
α1 chain expression was analyzed by real time RT-PCR. *P versus con-
trol (Ctl; without vitamin D3 or gal-3); **p versus 1 μg gal-3 alone; n = 
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of vitamin D3 since it has been shown that vitamin D3 ana-
logues have immunomodulatory effects [47].
Conclusion
The presence of extracellular gal-3 in the vicinity of chondro-
cytes and osteoblasts causes deleterious effects by both
downregulating the anabolic processes and upregulating the
catabolic processes. In fact, this factor may participate in car-
tilage destruction and subchondral bone erosion, particularly
during the highly inflammatory phases of OA.
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